Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | GSR | P00390 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | PRNP | P04156 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23904881 | 0.99 | MBNL1 (0.76) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL23904666 | 0.99 | MBNL1 (0.76) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL23795497 | 0.97 | MBNL1 (0.75) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL7869225 | 0.94 | MBNL1 (0.81) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL27739751 | 0.94 | ADORA2A (0.74) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL3400316 | 0.93 | MBNL1 (0.73) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL6895389 | 0.93 | MBNL1 (0.67) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL20087027 | 0.93 | MBNL1 (0.80) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL20087077 | 0.93 | MBNL1 (0.80) | MBNL1ADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL20087053 | 0.93 | MBNL1 (0.80) | MBNL1ADORA2AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4352054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023225631-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021202669-A2 | NUCLEOSIDE AND NUCLEOTIDE CONJUGATE COMPOUNDS AND USES THEREOF | REYOUNG CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | MYC, MYCBP, TNS4 | MBNL1 327/4885ADORA2A 3812/4885MEN1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.